Vnitr Lek 2020, 66(8):513-517 | DOI: 10.36290/vnl.2020.149

Fixed-dose combination of rosuvastatin and ezetimibe

Martin Šatný
Centrum preventivní kardiologie, 3. interní klinika - klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze

Atherosclerotic cardiovascular diseases (ASCVD) play a significant role in morbidity and mortality not only in developed but also increasingly in developing countries. The only causal risk factor (RF) of ASKVO is LDL-cholesterol. The basic pillar of pharmacotherapy of dyslipidaemias are statins, which should be titrated to the maximum (tolerated) dose and then combined with ezetimibe if the LDL-cholesterol targets for the specific categories of CV risk are not reached. Combination therapy is known to be far more effective than increasing the statin dose. Fixed combinations of statins with ezetimibe can be advantageously used to improve adherence.

Keywords: cardiovascular disease, CV risk, dyslipidemia, rosuvastatin, ezetimibe, fixed combination.

Published: December 15, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šatný M. Fixed-dose combination of rosuvastatin and ezetimibe. Vnitr Lek. 2020;66(8):513-517. doi: 10.36290/vnl.2020.149.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ÚZIS. Zdravotnická ročenka České republiky 2018, dostupné z: https://www.uzis.cz/res/f/008280/zdrroccz-2018.pdf.
    2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (online). 2019 (cit. 2019-09-01). DOI: 10.1093/eurheartj/ehz455. ISSN 0195-668X. Dostupné z: https://academic.oup.com/eurheartj/advance‑article/doi/10.1093/eurheartj/ehz455/5556353 Go to original source... Go to PubMed...
    3. Scheidt‑Nave C, DU Y, Knopf H, et al. Verbreitung von Fettstoffwechselstörungen bei Erwachsenen in Deutschland. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz(online). 2013; 56(5-6): 661-667 (cit. 2019-08-14). DOI: 10.1007/s00103-013-1670-0. ISSN 1436-9990. Dostupné z: http://link.springer.com/10.1007/s00103-013-1670-0. Go to original source... Go to PubMed...
    4. Sanin V, Koenig W. Therapie der Hypercholesterinämie in der Primärprävention. DMW - Deutsche Medizinische Wochenschrift (online). 2019; 144(05): 322-328 (cit. 2019-08-14). DOI: 10.1055/a-0657-1668. ISSN 0012-0472. Dostupné z: http://www.thieme‑connect.de/DOI/DOI?10.1055/a-0657-1668 Go to original source... Go to PubMed...
    5. Rosuvastatin (SPC). Souhrn informací o přípravku. Dostupný na: www.sukl.cz.
    6. Rosuvastatin/ezetimib (SPC). Souhrn informací o přípravku. Dostupný na: www.sukl.cz.
    7. Lund TM, Torsvik H, Falch D, et al. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol 2002; 90(7): 784-786. Go to original source... Go to PubMed...
    8. Rosuvastatin. Pubchem diabase. Dostupné z: https://pubchem.ncbi.nlm.nih.gov/compound/Rosuvastatin#section=Top.
    9. Ezetimib (SPC). Souhrn informací o přípravku. Dostupný na: www.sukl.cz.
    10. Ezetimib. Pubchem diabase. Dostupné z: https:/ / pubchem.ncbi.nlm.nih.gov/ compound/ Ezetimibe#section=Top.Drug Information 2016. Bethesda: American Society of Health‑System Pharmacists 2016: 1865-1866.
    11. Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non‑alcoholic fatty liver disease/non‑alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32. doi: 10.1016/j.metabol.2017. 02. 014. Go to original source...
    12. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97(8 A): 52C- 60C. Go to original source... Go to PubMed...
    13. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. The Lancet (online). 2012; 380(9841): 565-571 (cit. 2020-11-14). ISSN 01406736. Dostupné z: doi:10.1016/S0140-6736(12)61190-8. Go to original source... Go to PubMed...
    14. Šatný M, Vrablík M. Desatero užití ezetimibu aneb stručný průvodce jeho použitím v současnosti. AtheroRev 2019; 4(3): 181-184.
    15. Hong SJ, Jeong HS, Ahn, JC, et al. A phase III, multicenter, randomized, double‑blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I‑ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther 2018; 40(2): 226-241. doi: 10.1016/ j.clinthera.2017. 12. 018. Go to original source... Go to PubMed...
    16. Kim KJ, Kim SH, Yoon YW, et al. Effect of fixed‑dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‑ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther 2016; 34(5): 371-382. doi: 10.1111/ 1755-5922.12213. Go to original source... Go to PubMed...
    17. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-680. Go to original source... Go to PubMed...
    18. Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up‑titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 2011; 108: 523-530. Go to original source... Go to PubMed...
    19. Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high‑risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86-93. Go to original source... Go to PubMed...
    20. Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015; 56: 278-228. Go to original source... Go to PubMed...
    21. Kyselák O, Šoška V. Fixní kombinace rosuvastatinu s ezetimibem - lékový profil. Kardiol Rev Int Med 2018; 20(2): 142-146.
    22. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine (online). 2015; 372(25): 2387-2397 (cit. 2019-09-12). DOI: 10.1056/NEJMoa1410489. ISSN 0028-4793. Dostupné z: http://www.nejm.org/doi/10.1056/NEJMoa1410489. Go to original source... Go to PubMed...
    23. Rossebo AB, Pedersen TR, Boman K, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. New England Journal of Medicine (online). 2008; 359(13): 1343-1356 (cit. 2019-09-12). DOI: 10.1056/NEJMoa0804602. ISSN 0028-4793. Dostupné z: http://www.nejm.org/doi/abs/10.1056/NEJMoa0804602. Go to original source... Go to PubMed...
    24. Baigent, C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‑controlled trial. The Lancet (online). 2011; 377(9784): 2181-2192 (cit. 2019-09-12). DOI: 10.1016/S0140-6736(11)60739-3. ISSN 01406736. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0140673611607393. Go to original source... Go to PubMed...
    25. Soška V. Vliv kombinace simvastatinu s ezetimibem na krevní lipidy a na kardiovaskulární příhody u diabetiků (komentář k výsledkům subanalýzy studie IMPROVE‑IT). Vnitř Lék 2015; 61: 965-969. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.